Multi-layered genetic approaches to identify approved drug targets

preprint OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-07 ⓘ

This study compares gene-prioritization methods for identifying drug targets across 30 clinical traits, finding that GWAS performs best and highlighting the risk of network diffusion artifacts due to data circularity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-15 · read from full text ⓘ

This study systematically compared four genetic approaches—GWAS, eQTL-GWAS, pQTL-GWAS, and whole exome sequencing burden tests—to evaluate their ability to prioritize drug target genes across thirty common clinical traits. The researchers found that standard GWAS methods performed significantly better than expression or protein quantitative trait locus integrations, while network diffusion strategies showed promise but risked circularity due to gene degree biases. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Drugs targeting genes that harbor natural variations associated with the disease the drug is in-dicated for have increased odds to be approved. Various approaches have been proposed to iden-tify likely causal genes for complex diseases, including gene-based genome-wide association stud-ies (GWAS), rare variant burden tests in whole exome sequencing studies (Exome) or integration of GWAS with expression/protein quantitative trait loci (eQTL-GWAS/pQTL-GWAS). Here, we compare gene-prioritization approaches on 30 common clinical traits and benchmarked their ability to recover drug target genes defined using a combination of five drug databases. Across all traits, the top pri-oritized genes were enriched for drug targets with odds ratios (ORs) of 2.17, 2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We quantified the perfor-mance of these methods using the area under the receiver operating characteristic curve as metric, and adjusted for differences in testable genes and data origins. GWAS performed significantly better (54.3%) than eQTL (52.8%) and pQTL-GWAS (51.3%), but not significantly so against the Exome ap-proach (51.7% vs 52.8% for GWAS restricted to UK Biobank data). Furthermore, our analysis showed increased performance when diffusing gene scores on gene networks. However, substantial improve-ments in the protein-protein interaction network may be due to circularity in the data generation process, leading to the node (gene) degree being the best predictor for drug target genes (OR = 8.7, 95% CI = 7.3-10.4) and warranting caution when applying this strategy. In conclusion, we systematically as-sessed strategies to prioritize drug target genes highlighting promises and potential pitfalls of current approaches.
Full text 121,737 characters · extracted from oa-pdf · 10 sections · click to expand

Abstract

Drugs targeting genes that harbor natural variations associated with the disease the drug is in- dicated for have increased odds to be approved. Various approaches have been proposed to iden- tify likely causal genes for complex diseases, including gene-based genome-wide association stud- ies (GWAS), rare variant burden tests in whole exome sequencing studies (Exome) or integration of GWAS with expression/protein quantitative trait loci (eQTL-GWAS/pQTL-GWAS). Here, we compare gene-prioritization approaches on 30 common clinical traits and benchmarked their ability to recover drug target genes defined using a combination of five drug databases. Across all traits, the top pri- oritized genes were enriched for drug targets with odds ratios (ORs) of 2.17, 2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We quantified the perfor- mance of these methods using the area under the receiver operating characteristic curve as metric, and adjusted for differences in testable genes and data origins. GWAS performed significantly better (54.3%) than eQTL (52.8%) and pQTL-GWAS (51.3%), but not significantly so against the Exome ap- proach (51.7% vs 52.8% for GWAS restricted to UK Biobank data). Furthermore, our analysis showed increased performance when diffusing gene scores on gene networks. However, substantial improve- ments in the protein-protein interaction network may be due to circularity in the data generation process, leading to the node (gene) degree being the best predictor for drug target genes (OR = 8.7, 95% CI = 7.3-10.4) and warranting caution when applying this strategy. In conclusion, we systematically as- sessed strategies to prioritize drug target genes highlighting promises and potential pitfalls of current approaches. 2 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Introduction1 Drugs whose targets have genetic support were found to be more likely to succeed in clinical trials [1, 2].2 Although multiple methods have been proposed to establish such genetic support, leveraging genetic3 data to find disease genes and ultimately drug targets has proven to be challenging [3, 4, 5, 6]. The4 most straightforward approach maps genome-wide association studies (GWASs) signals to the closest5 genes with more sophisticated methods incorporating linkage disequilibrium (LD) structure and gene6 annotation information to compute gene scores [7, 8, 9]. Over the past decade, large-scale molecular7 quantitative trait loci (mQTL) datasets facilitated the discovery of disease mechanisms and the identifi-8 cation of potential new drug targets [10, 11, 12, 13, 14, 15]. Several methods, including Mendelian ran-9 domization studies, transcriptome-wide association studies and colocalization methods have integrated10 expression and protein QTL data with GWAS studies to pinpoint likely causal genes for complex traits11 and diseases [16, 17, 18, 19, 20, 21, 22]. More recently, the availability of high-throughput sequencing12 data enabled the discovery and analysis of rare variants and their aggregated effects to reveal gene-13 disease associations [23, 24]. Whole exome sequencing (WES) in the UK Biobank (UKBB) showed that14 genes prioritized this way are 3.6 times more likely to be targets of drugs approved by the Food and15 Drug Administration (FDA) [25].16 17 Genes prioritised by GWASs, mQTL-GWAS integration methods and WES burden tests may not be18 drug targets themselves, but up- or downstream of those in pharmacological pathways. Propagating19 gene prioritization scores on networks has proven to be a promising approach to identify known drug20 target genes [26, 27, 28, 29, 30]. Starting from seed genes (i.e., prioritized disease-associated genes),21 network connectivity can identify neighbouring genes that strongly interact with disease genes, but lack22 a direct genetic evidence that explain their therapeutic effect. Gene networks can be derived from lit-23 erature or high-throughput experiments and thus are prone to yield very different results when used for24 (seed) gene score diffusion [31].25 26 Here, we took a comprehensive approach to examine the contribution of each method component27 3 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint to the success of drug target prioritization. First, we focused on four different approaches to prioritise28 (seed) genes: 1) LD-aware gene score computation from the largest GWASs with full publicly available29 summary statistics (Pascal [9]); 2) Mendelian Randomisation (MR) combining tissue-wide expression30 QTLs and GWAS (eQTL-GWAS); 3) MR combining plasma protein QTL with GWAS (pQTL-GWAS);31 4) UKBB WES burden tests (Exome). We then used three different networks to diffuse the seed32 gene scores: 1) STRING protein-protein interaction (PPI) network [32]; 2) an RNA-seq co-expression33 network [33]; 3) the FAVA network [34]. All 12 combinations of the four seed generating methods and the34 three networks were applied to thirty traits (Figure 1) using five different reference sets of target genes35 (DrugBank [35], Ruiz et al. [36], ChEMBL [37], DGIdb [38] and STITCH [39]). Overall, we provide an36 in-depth comparison of all combinations of these approaches, identifying their respective strengths and37 caveats.38 4 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint GWAS GWAS p-values QTL - GWAS Gene LD Reference Gene scoring GWAS Mendelian randomization pQTLs - Tissue-wide - Whole blood - Plasma Gene p-values Exomea Gene burden test # variants Trait Gene p-values Summary statistics Summary statistics Rare variants (MAF ≤ 1%) in WES Considered variants: - putative loss-of- function - missense Tsum = /uni2211z2 i Tsum /uni223C/uni2211/uni03BBi /uni03C72 1 Protein Transcript eQTLs pQTL b GWAS b /uni03B2MR (Causal effect) eQTL b GWAS b /uni03B2MR Gene 0 1 2 b eQTL-GWAS pQTL-GWAS Exome GWAS DGIdb STITCH ChEMBL DrugBank Ruiz et al. ChEMBL Drug target genes Prioritized disease genes Enrichment analysis (OR) Area under the ROC curve (AUC) Indication Drug c Network diffusion Protein-protein interaction (STRING) Co-expression (CoXRNAseq) Co-expression & proteomics (FAVA) Prioritized disease gene (GWAS, QTL-GWAS, Exome) Drug target gene slope = network diffusion scores (x3) network diffusion scores restart parameter r (diffusion strength) Gene p-values Gene scores 5 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 1: Overview of the analysis workflow. a Three different gene prioritization methods were tested in this study. The first one uses GWAS summary statistics as input (GWAS); the second combines molecular QTL and GWAS summary statistics (QTL-GWAS): either expression QTL (eQTL) or protein QTL (pQTL) data; the third leverages individual-level whole exome sequencing (WES) data (Exome). In the GWAS method, gene p-values are based on the sum of squared SNP z-scores (T sum) that fol- lows a weighted χ2 1 distribution. The QTL-GWAS method integrates QTL and GWAS summary statistics through Mendelian randomization (MR). MR causal effect sizes (β MR) are calculated from GWAS and mQTL effect sizes (GWAS b and mQTL b, respectively) and gene scores are the corresponding p- values. The Exome method aggregates rare variants from WES data. Putative loss-of-function and missense variants with minor allele frequencies (MAF) below 1% are collapsed in burden tests which

Results

in gene p-values. The different approaches were benchmarked for their ability to prioritize drug target genes. b The effect of network diffusion using three different network types and different diffusion strengths (i.e. restart parameter r) was evaluated. Drug target genes may only be prioritized following signal propagation from neighboring disease genes. c Diseases were linked to target genes through public drug databases: first, we used drug-indication information to connect the 30 traits to drugs and then leveraged drug-target information to link the drugs to genes. Prioritized disease genes and cor- responding diffusion scores (obtained via strategies described in panel a and b) were then tested for overlap with drug target genes through Fisher’s exact tests resulting in odds ratios (ORs) and through area under the receiver operating characteristic curve (AUC) values. Results39 Overview of the analysis40 In this study, we calculated gene prioritization scores and tested their ability to identify drug targets41 across thirty traits (Figure 1). We focused on three types of methods termed GWAS, QTL-GWAS and42 Exome that allow the computation of gene scores provided genetic association data (Figure 1a).43 44 The GWAS method takes as input GWAS summary statistics together with a matching LD reference45 panel. Gene p-values are calculated based on the sum of squared test statistics for SNPs falling into46 the gene region [9]. The QTL-GWAS methods integrate GWAS summary statistics with molecular QTL47 data for the gene of interest. We calculated gene scores using i) expression QTL data (eQTL-GWAS )48 from the largest available whole blood eQTL study (eQTLGen study, n = 31,684) as well as tissue-wide49 eQTL data from the GTEx consortium v8 (n = 65-573 for 48 tissue types) and ii) protein QTL data50 (pQTL-GWAS) from the largest available plasma pQTL study (deCODE study, n = 35,559) [14] and i.51 Integration was done by performing Mendelian randomization (MR) analyses using either the protein52 6 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint or transcript as exposure and the GWAS trait as outcome. If not specified otherwise, the eQTL-GWAS53

Method

refers to the tissue-wide analysis in which the eQTLGen and GTEx data are combined by54 considering the tissue for which the MR effect was the most significant (Methods). While the GWAS55 and QTL-GWAS methods focuse on common genetic variants, the Exome method considers only56 rare variants from WES data with minor allele frequencies (MAF) below 1%. Gene scores were57 based on gene burden tests that aggregate putative loss-of-function and missense variants, and we58 used the resulting p-values from the WES analysis in the UKBB [25]. To allow for a fair comparison59 with the Exome method while also exploiting disease-specific consortia GWAS summary statistics60 with maximized case counts, we calculated gene prioritization scores for the GWAS and QTL-GWAS61

Methods

using both consortia GWAS and UKBB GWAS data (Table S1-3; Methods).62 63 Disease genes may not coincide with drug target genes, but they may be in close proximity in terms64 of molecular interaction (Figure 1b). Through diffusion based on random walks, we leveraged network65 connectivity to prioritize neighbours of disease genes, which may be drug targets. We tested this66 hypothesis on three different network types: the STRING PPI network which relies on literature67 interactions among other data types [32], a gene co-expression network based on 31,499 RNA-seq68 samples (CoXRNAseq ) [33], and gene co-expression network based on single cell RNA-seq and69 proteomics data (FAVA) [34]. Gene prioritization scores were obtained following diffusion at six different70 restart parameter values (r = 0, 0.2, 0.4, 0.6, 0.8, 1) (Methods).71 72 Disease drug target genes were defined using public databases. Specifically, drug-disease indica-73 tion were retrieved from DrugBank [35], Ruiz et al. [36], and ChEMBL [37], while drug-drug target74 pairs originate from DGIdb [38], STITCH [39], and ChEMBL [37]. Drug target enrichment analyses75 were calculated for the following five database combinations: DrugBank/DGIdb, DrugBank/STITCH,76 Ruiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL.77 78 Finally, prioritized disease genes, defined as the top 1% of genes identified through the 12 combinations79 7 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint of gene prioritization and network diffusion methods (5% for combinations involving the pQTL-GWAS80

Method

to account for the smaller set of testable genes), were then tested for enrichment with the five81 drug target genes using Fisher’s exact test (Figure 1c). Background genes were defined as all genes that82 could be tested by the respective method, and sensitivity analyses were performed on background genes83 testable for all methods. Second, we calculated the area under the receiver operating characteristic84 curve (AUC) values which has the advantage of not requiring any thresholds. To compute a combined85 enrichment score per method, we aggregate results across traits and drug databases termed overall86 ORs or overall AUC values (Methods).87 Concordance of prioritized genes among gene scoring methods88 We first analyzed whether genes prioritized by the GWAS, QTL-GWAS and Exome methods were89 concordant (Figure 2). For each of the thirty traits (Figure 2a), we calculated gene scores for the90 testable autosomal protein-coding genes (GWAS: ∼19,150, eQTL-GWAS: ∼12,550 (blood) and ∼16,25091 (tissue-wide), pQTL-GWAS: ∼1,870, Exome: ∼18,800). In the tissue-wide eQTL-GWAS method, the92 tissue with the most significant MR p-value was selected. In Figure S1, we show the proportion of genes93 mapped to a particular tissue category. The contribution of glandular-endocrine, neural central nervous94 system (CNS) and whole blood (eQTLGen) tissue categories were the highest (respective means of95 15.3%, 12.8%, and 12.6% across the thirty traits; Table S4-5). Although each trait had genes mapped96 to nearly all tissues, a few distinctive patterns could be observed: cardiac muscle tissues contributed97 the most to atrial fibrillation (16.4%), vascular tissues the most to coronary artery disease (16.5%)98 followed by diastolic (11.1%) and systolic (9.9%) blood pressure, and the neural CNS contributed the99 most to schizophrenia (16.9%) and bipolar disease (16.6%).100 101 8 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint 0 2 4log−OR Alzheimer Asthma Atopic dermatitis Atrial fibrillation Bipolar CAD CKD COPD Diastolic BP Endometriosis Epilepsy Glaucoma IBD IBS LDL MDD Multiple sclerosis Osteoarthritis Osteoporosis Parkinson's disease Pneumonia Psoriasis Rheumatoid arthritis Schizophrenia Stroke Systolic BP T1D T2D Total cholesterol VTE 0.0 2.5 5.0 7.5 10.0 0.0 2.5 5.0 7.5 10.0 Top gene percentile (%) log−OR eQTL−GWAS vs GWAS 0.0 2.5 5.0 7.5 10.0 0.0 2.5 5.0 7.5 10.0 Top gene percentile (%) log−OR GWAS vs Exome 0.0 2.5 5.0 7.5 10.0 0.0 2.5 5.0 7.5 10.0 Top gene percentile (%) log−OR eQTL−GWAS vs Exome 0.0 2.5 5.0 7.5 10.0 0.0 2.5 5.0 7.5 10.0 Top gene percentile (%) log−OR eQTL−GWAS vs pQTL−GWAS (blood) Alzheimer Asthma Atopic dermatitis Atrial fibrillation Bipolar CAD CKD COPD Diastolic BP Endometriosis Epilepsy Glaucoma IBD IBS LDL MDD Multiple sclerosis Osteoarthritis Osteoporosis Parkinson's disease Pneumonia Psoriasis Rheumatoid arthritis Schizophrenia Stroke Systolic BP T1D T2D Total cholesterol VTE 0.2 0.3 0.4 0.5 0.6 0.7 Q1 Q2 Q3 Q4 Transcript Heritability − quartile Spearman ρ eQTL−GWAS vs GWAS 0.1 0.2 0.3 0.4 Q1 Q2 Q3 Q4 Transcript Heritability − quartile Spearman ρ eQTL−GWAS vs pQTL−GWAS (blood) a b c d 9 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 2: Evaluating the concordance of prioritized genes among methods. a Thirty different traits/drug indications were tested in this study. b The top prioritized genes between pairs of methods were com- pared at different thresholds for each trait (legend shown in a). The logarithm of odds ratios (log-OR) were calculated from Fisher’s exact tests. Log-ORs are only plotted for percentiles at which common genes between pairs of methods were found. Comparisons were conducted on the same background genes and same data origins (i.e., on UK Biobank GWASs for comparisons with the Exome method). Tissue-wide eQTL-GWAS gene prioritizations were considered for the comparison with the GWAS and Exome methods, and the blood-only eQTL-GWAS gene prioritization method for the comparison with the pQTL-GWAS method. c Spearman correlations calculated per trait between the gene significance (-log10(p-values)) from the GWAS and tissue-wide eQTL-GWAS methods. The analysis was conducted per trait on all common genes ( ∼16,100) stratified into quartiles according to transcript heritability (in cis). d Spearman correlations calculated per trait between gene Mendelian randomization (MR) causal effect sizes (βMR) from the blood eQTL-GWAS and pQTL-GWAS methods. The analysis was conducted on all common genes (∼1,370) stratified into quartiles according to the transcript heritability. In c and d, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima (Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points corresponding to individual traits from a. The concordance of prioritized genes among pairs of methods is summarized in Figure 2b. For each102 trait, we calculated Fisher’s exact tests between the top prioritized genes at thresholds ranging from the103 top 0.1%-10% (Methods). The overlap was the highest between the GWAS and eQTL-GWAS methods.104 At 1%, the median odds ratio (OR) was 212.2 which dropped to 51.0 and 22.1 at 5% and 10%, respec-105 tively. The concordance between GWAS and eQTL-GWAS prioritized genes was highest for transcripts106 with high heritabilities (Figure 2c; Methods). Similarly, the agreement between the eQTL-GWAS (whole107 blood) and pQTL-GWAS (blood plasma) increased with increasing transcript heritabilities (Figure 2d).108 Overall, the median ORs between these two methods was 8.5 and 4.6 at the top 5% and 10%, respec-109 tively. The overlap of prioritized genes was the lowest with the Exome method. The top 1% GWAS vs110 Exome and eQTL-GWAS vs Exome overlaps (based only on UKBB GWAS summary statistics), yielded111 median ORs of 1.7 and 1.9, respectively which dropped to 1.0 at 10% for both methods.112 Enrichment of prioritized genes for drug targets113 Next, we assessed the extent to which prioritized genes overlapped with drug target genes. For114 each trait, we conducted enrichment analyses for the GWAS, eQTL-GWAS, pQTL-GWAS and Exome115

Methods

using our five definitions of drug target genes.116 10 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint 117 In Figure 3a, we show the resulting ORs for the DrugBank/DGIdb database combination. Across118 methods, genetic support for drug targets was the highest for LDL and total cholesterol (average ORs119 of 5.99 and 6.12, respectively). Lowest enrichment ratios were obtained for neuro-psychiatric traits120 (average OR of 1.56) and glaucoma (average OR of 1.14). The average OR across traits was 2.48,121 2.68, 1.65, and 1.26 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.122 We explored a range of top disease gene percentiles (0.1-5%) and the corresponding ORs are123 shown in Figure 3b. Restricting disease genes to the top 0.1% for all methods increased the average124 ORs without changing the method ranking with average ORs of 3.68, 4.02, 2.40, and 1.44 for the125 GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We further analyzed whether126 identified drug targets were the same across methods and found that prioritized drug target genes were127 similar between GWAS and eQTL-GWAS methods (average Jaccard index of 0.39), less so between128 eQTL-GWAS and pQTL-GWAS methods (blood tissues; average Jaccard index of 0.15) and were very129 different from Exome identified targets (average Jaccard index of 0.06 between GWAS & Exome and130 eQTL-GWAS & Exome methods). Average AUC values across traits were of 53.4%, 51.9%, 50.5% and131 49.9% for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods (Figure 3c).132 133 While the number of drugs reported per indication was similar across databases (average of 43.9,134 41.8 and 40.4 for Ruiz et al., ChEMBL and DrugBank, respectively), the average number of reported135 drug targets was much higher for Ruiz/STITCH (285), Ruiz/DGIdb (274.8), Drugbank/DGIdb (263.4)136 and Drugbank/STITCH (244.2) than for ChEMBL/ChEMBL (24.8; Table S7). We repeated drug target137 enrichment calculations for all drug database combinations (Figure 3d, Figure S2). The average OR138 for the GWAS/eQTL-GWAS methods were 2.48/2.68, 2.80/2.53, 2.18/2.12, 1.78/1.61 and 1.78/1.51 for139 Drugbank/DGIdb, ChEMBL/ChEMBL, Ruiz/DGIdb, Ruiz/STITCH and Drugbank/STITCH, respectively.140 Overall, the variability in ORs across traits was the highest in the ChEMBL database (Figure 3d, Figure141 S2), likely due to the low average number of reported drug targets which leads to very high ORs when142 drug targets figured among the prioritized genes (e.g. for LDL and total cholesterol), but for many traits143 11 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint drug target genes were not among prioritized genes (e.g. for type 1 diabetes, atopic dermatitis and144 inflammatory bowel disease).145 146 Since enrichment results can differ widely across traits and reference databases, we calculated overall147 enrichment and AUC values across traits and drug databases, including sensitivity analyses on UKBB148 data only and common background genes (Table S9, Figure S4; Methods). The overall ORs were 2.17149 (UKBB: 1.72), 2.04 (UKBB: 1.67), 1.81 and 1.31 (UKBB: 1.30) for the GWAS, eQTL-GWAS, Exome and150 pQTL-GWAS methods, respectively. There were no significant differences between these four methods151 in terms of enrichment OR (Pdiff > 0.05 including in the sensitivity analyses). Overall AUCs were 54.3%152 (UKBB: 52.8%), 52.8% (UKBB: 51.4%), 51.7% and 51.3% (UKBB: 50.6%) for the GWAS, eQTL-GWAS,153 Exome and pQTL-GWAS methods, respectively. Judging by the AUC values, GWAS performed signifi-154 cantly better than eQTL-GWAS (Pdiff = 3.1e-5) also when only considering testable eQTL genes (P diff =155 2.9e-4). Significantly higher AUC values were obtained for the GWAS compared to Exome on consortia156 data (Pdiff = 2.2e-4) which was no longer the case on UKBB data (P diff = 0.06). The difference between157 eQTL-GWAS and Exome was not significant on either dataset (P diff of 0.12 and 0.77 on consortia and158 UKBB data, respectively). The number of testable genes was much lower for the pQTL-GWAS method159 (∼1,870 genes). With this set of background genes, GWAS still scored a higher overall AUC (55.1%,160 Pdiff = 2.1e-3). No difference was observed between the pQTL-GWAS and tissue-wide or whole blood161 eQTL-GWAS methods (Pdiff of 0.66 and 0.87, respectively).162 12 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint 0.35 0.40 0.45 0.50 0.55 0.60 GWAS eQTL−GWAS Exome pQTL−GWAS AUC 0 10 20 0 1 2 3 4 5 Top gene percentile (%) OR GWAS eQTL−GWAS Exome pQTL−GWAS Panel a,d* *pQTL-GWAS 1 8 64 DrugBank / DGIdb Ruiz / DGIdb Ruiz / STITCH DrugBank / STITCH ChEMBL / ChEMBL OR Glaucoma Bipolar MDD Schizophrenia Alzheimer Parkinson's disease Epilepsy Multiple sclerosis Pneumonia COPD Asthma IBS IBD Psoriasis Atopic dermatitis Osteoarthritis Osteoporosis Rheumatoid arthritis Stroke Atrial fibrillation Diastolic BP Systolic BP CAD VTE Endometriosis CKD T1D T2D Total cholesterol LDL eQTL−GWAS vs GWAS GWAS vs ExomeeQTL−GWAS vs Exome eQTL−GWAS vs pQTL−GWAS (blood) 1.00 0.75 0.50 0.25 0.00 eQTL−GWAS vs Exome GWAS vs Exome eQTL−GWAS vs pQTL−GWAS eQTL−GWAS vs GWAS EndometriosisRheumatoid arthritis OsteoporosisMultiple sclerosis Parkinson's disease Total cholesterol PsoriasisAtrial fibrillation Glaucoma IBS MDDSystolic BP LDL CKD Diastolic BP Asthma IBD CAD T2D Schizophrenia Atopic dermatitis VTE Osteoarthritis Bipolar Epilepsy COPDAlzheimer Pneumonia Stroke T1D Jaccard index 1.00 0.75 0.50 0.25 0.00 Common identified drug targets 1 4 2 1 0 4 3 4 2 7 5 4 1 4 4 7 0 0 2 0 1 0 3 2 2 1 6 4 3 7 11 10 0 2 4 1 2 1 2 2 5 2 5 9 2 1 2 1 6 3 8 11 2 5 8 9 6 2 4 10 4 2 4 4 1 5 6 6 10 12 18 18 5 9 0 8 4 3 7 8 6 10 14 16 8 13 20 17 5 7 11 13 5 7 4 7 0 0 1 1 1 2 4 6 1 2 1 1 6 8 9 10 6 15 13 13 6 13 13 14 Glaucoma Bipolar MDD Schizophrenia Alzheimer Parkinson's disease Epilepsy Multiple sclerosis Pneumonia COPD Asthma IBS IBD Psoriasis Atopic dermatitis Osteoarthritis Osteoporosis Rheumatoid arthritis Stroke Atrial fibrillation Diastolic BP Systolic BP CAD VTE Endometriosis CKD T1D T2D Total cholesterol LDL 0 2 4 6 8 OR MetabolicGenito- urinaryCirculatory systemMusculoskel. & connect. tissueSkinDigestive systemRespiratoryNervous systemPsychiatricEye a # Identified drug targets GWAS eQTL-GWAS Exome pQTL-GWASICD10 classification b c eQTL-GWAS & GWAS GWAS & Exome eQTL-GWAS & Exome eQTL-GWAS & pQTL-GWAS (blood) Jaccard index 1.000.750.500.250.00 Common identified drug targets d 13 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 3: Enrichment for drug target genes. a Left: Barplot with odds ratios (ORs) calculated from Fisher’s exact tests between drug target genes and the top 1% (5% for pQTL-GWAS) prioritized genes for the four tested methods and thirty traits, classified according to trait category. Drug target genes were defined by DrugBank/DGIdb, and only drug target genes that could be tested by the respective method were considered. The number on the right of each bar indicates the number of identified drug target genes. Right: Overlap of identified drug target genes between pairs of methods quantified through the Jaccard index. The blood-only eQTL-GWAS gene prioritization method was used for the comparison with the pQTL-GWAS method. Plots using UKBB GWASs-only are shown in Figure S3. b ORs at different top prioritised gene percentiles for the four methods. The plotted dots correspond to the median OR across the thirty traits, and the shaded area bounds the 10% and 90% percentiles. c Boxplots showing the area under the receiver operating characteristic curve (AUC) values. AUC values were calculated for each trait as indicated by the points (legend in Figure 2a) and using the same background genes and drug target definitions as in a. d ORs calculated for the five drug target definitions and for all four methods (legend in b). The OR was set to 1 for traits with no identified drug target genes. In b and d, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima (Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points outside representing potential outliers. Examples of drug target prioritization ranks163 In Figure 4, we highlight drug targets and their gene prioritization ranks for a few examples (complete list164 in Table S10). Major antihypercholesterolemic drug targets PCSK9 (evolocumab, alirocumab), HMGCR165 (statins) and NPC1L1 (ezetimibe) were top ranked by all methods (except for no pQTLs being available166 for HMGCR and NPC1L1; Figure 4a). HCN4, the target of antiarrhythmic drug dronedarone, was priori-167 tized as a disease gene for atrial fibrillation only through the GWAS method. Although highly expressed168 in the atrial appendage and left ventricle of the heart, no eQTL was reported for this gene (Figure 4b).169 Several antiepileptic drugs target SCN1A which was highly prioritized by the GWAS and eQTL-GWAS170

Methods

with the strongest MR effect found in the nucleus accumbens (basal ganglia) of the brain (Fig-171 ure 4c). Antiplatelet drug dipyrimadole used in the prevention and treatment of vascular diseases such172 as stroke and coronary artery disease is listed to target 23 genes of the PDE superfamily in ChEMBL.173 Of these, four (PDE4D, PDE3A, PDE3B, PDE6B) were ranked in the top 1% by the exome method for174 stroke (Figure 4d). None of the other methods prioritized any of these 23 genes. For coronary artery dis-175 ease, another superfamily member (PDE5A) had a low ranking (< 2%) for the GWAS and QTL-GWAS176 methods, supported by solid GWAS and e/pQTL colocalisation (Figure 4e).177 14 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint da b Dipyri- damole Drone- darone PCSK9 HMGCR PDE3B PDE4D NPC1L1 HCN4 StrokeLDL Atrial fibrillation 25 (0.15%) 18 (0.92%) 1 (<0.01%) 1-52 (<0.01%) 1-52 (<0.01%) 12 (0.07%) no pQTL 10 (0.05%) 53 (0.33%) NA 5 (0.03%) 175 (0.92%) no eQTL eQTL-GWAS NA pQTL-GWAS 9,010 (47.9%) Exome 12 (0.06%) GWAS Artery - Aorta Artery - Coronary Artery - Tibial Brain - Amygdala Brain - Ant. cing. cortex Brain - Caudate (basal ganglia) Brain - Cerebellar Hemisphere Brain - Cerebellum Brain - Cortex Brain - Frontal Cortex (BA9) Brain - Hippocampus Brain - Hypothalamus Brain - Nuc. acc. (basal ganglia) Brain - Putamen (basal ganglia) Brain - Spinal cord (cervical c-1) Brain - Substantia nigra Heart - Atrial Appendage Heart - Left Ventricle Pituitary Testis Whole Blood 0 10 20 30 40 TPM Bulk tissue gene expression for HCN4 > 18% > 12% no pQTL / NA < 1% c SCN1AEpilepsy 13 (0.08%) no pQTL 472 (2.5%) 2 (<0.01%) e Brain − basal ganglia Brain − cortex Brain cerebellum Testis −0.025 0.000 0.025 0.050 MR effect size Position on chrom 4 [Mb] −log10(PGWAS) 0 2 4 6 8 10 Position on chrom 4 [Mb] −log10(PpQTL) 0 20 40 60 80 100 120 Position on chrom 4 [Mb] −log10(PeQTL) 0 10 20 30 40 50 120.0 120.2 120.4 120.6 120.8 Position on chrom 4 [Mb] Position on chr 4 [Mb] 0 5 10 15 − log10(p−value) 0 20 40 60 80 100 Recombination rate (cM/Mb) /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF /uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF/uni25CF/uni25CF/uni25CF /uni25CF/uni25CF/uni25CF /uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF/uni25CF /uni25CF rs7678555 0.2 0.4 0.6 0.8 r2 MYOZ2 USP53 C4orf3 FABP2 LINC01061 LOC645513 PDE5A LINC01365 MAD2L1 120 120.2 120.4 120.6 120.8 121 Position on chr4 (Mb) Plotted SNPs PDE5ACAD 150 (0.9%) 30 (1.6%) 7,212 (38.3%) 285 (1.5%)Dipyri- damole > 5% > 1% > 1% > 1% PDE3A PDE6B 15 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 4: Examples illustrating drug target genes and their prioritization ranks. a Three drug target genes (PCSK9 (evolocumab, alirocumab), HMGCR (statins) and NPC1L1 (ezetimibe) shown in purple) for LDL cholesterol (blue box) and their prioritization ranks (top percentiles shown in parentheses) of each of the four methods (GWAS in green, eQTL-GWAS in yellow, Exome in blue and pQTL-GWAS in red). Genes that were not testable by a given method are reported as NA (no e/pQTL means that the gene was measured, but had no QTL) and a range of ranks (i.e., 1-52) indicates tied p-values. b Top plot shows the prioritization ranks of HCN4, the target of antiarrhythmic drug, dronedarone. Bot- tom plot shows the gene expression profile of HCN4 across GTEx tissues (transcript per million - TPM) with “Testis”, “Heart – Atrial Appendage” and “Heart – Left Ventricle” dominating.c Top plot shows the prioritization ranks of SCN1A (Sodium Voltage-Gated Channel Alpha Subunit 1), a drug target gene of several antiepileptic drugs. Bottom plot shows Mendelian randomization (MR) effects (red dot) wih 95% CI (black bars) across tissues in which there was a significant eQTL. d Antiplatelet drug dipyrimadole and gene prioritization ranks of its multiple drug targets (a non-exhaustive selection) of the phosphodi- esterase (PDE) superfamily. e Top plot shows the gene prioritization ranks of PDE5A, another reported target for dipyrimadole. Bottom plot shows the regional SNP associations (-log 10(p-values)) with coro- nary artery disease (CAD; GWAS, green), PDE5A protein (pQTL, red) and PDE5A transcript (eQTL, yellow), respectively (red dashed lines indicate the significance thresholds of the respective SNP asso- ciation, and grey shade marks the position of PDE5A). Bottom row illustrates the positions and strand direction of the genes in the locus. Heritability and polygenicity of drug target transcripts and proteins178 It has been shown that drug target genes are more likely to have lower residual variance intolerance179 scores (RVIS), i.e., are less tolerant to change [1]. With the availability of large-scale eQTL and pQTL180 data, we tested whether drug target transcript or protein levels may be less impacted by genomic181 variations.182 183 To this end, we compared cis-heritabilities and polygenicities of drug target genes versus non-drug184 target genes that were measured in the respective studies (i.e., also those with no reported e/pQTLs;185 Methods). We conducted the analysis per trait and for each of the five drug target gene definitions.186 Overall, we observed that drug target genes were less heritable and more polygenic than non-drug187 target genes pointing towards a negative selection [40] (Figure S5). This trend was less pronounced188 for tissue-wide than for whole blood eQTLs, and was the strongest for pQTLs. Across QTL studies and189 drug databases, the traits for which drug targets were significantly less heritable and more polygenic190 differed substantially. However, in no scenario drug target genes were more heritable than non-drug191 target genes on either the transcript or protein-level (at a nominally significant level). Considering drug192 16 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint target genes defined by DrugBank/DGIdb for the plasma protein QTLs as an example: targets for traits193 from the circulatory system were all shown to be more polygenic, and targets for psychiatric traits were194 all less heritable at a nominally significant level.195 Network diffusion196 Finally, we assessed whether network diffusion can identify drug target genes for which there is no197 direct genetic evidence. Gene scores from prioritization methods defined the initial distribution p0 of198 the diffusion process. This process is regulated by a restart parameter r where lower values result in a199 wider diffusion (i.e., genes can be prioritized even when distant from initial disease genes; Methods).200 The stationary distribution was calculated for six different restart parameters, ranging from no diffusion201 (r = 1) to complete diffusion (r = 0). Since the set of testable proteins ( ∼1,870) is enriched for drug202 target genes (two-sided binomial test: p-value = 1.3e-47 for DrugBank/DGIdb; complete results in Table203 S15; Methods) AUC values were artificially inflated upon projecting the gene scores onto the network204 and pQTL-GWAS results are hence not discussed.205 206 Applying diffusion using the STRING network massively boosted the overlap between the diffused207 prioritized genes and the drug target genes (Figure 5a-b, Figure S6-7). At no diffusion, overall AUC208 values across the thirty traits were 54.3%, 52.8% and 51.7% for the GWAS, eQTL-GWAS and Exome209 methods, respectively, which increased to 68.9%, 67.7% and 66.9% at r = 0.6, and 73.5%, 72.9% and210 72.3% at r = 0.4 (Figure 5a, Figure S6, Table S12). The same trend was observed when calculating211 enrichment scores for the top 1% genes with overall ORs of 4.63, 5.21 and 5.07 at r = 0.4 (Figure 5b,212 Figure S7, Table S12). On the other hand, improvements were modest when considering co-expression213 networks. At r = 0.6, overall AUC values increased to 54.9%, 54.7% and 53.5% in case of the214 CoXRNAseq network. Although small, the difference was significant compared to no diffusion (P diff of215 5.11e-3, 4.12e-14 and 4.83e-5, respectively). Overall ORs at r = 0.6 were 2.28, 2.04 and 1.91 which216 were not significantly different (P diff > 0.05) compared to no diffusion. Likewise, in the FAVA network,217 overall AUC values at r = 0.6 were 55.9%, 54.2% and 53.6% (Pdiff compared to no diffusion of 2.23e-5,218 17 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint 3.08e-3 and 7.3e-6), and ORs 2.38, 2.02 and 1.77 (P diff > 0.05) for GWAS, eQTL-GWAS and Exome219 methods, respectively (Figure S6-7, Table S12-13).220 221 We further assessed which method’s AUC values benefited the most from network diffusion. To allow222 fair comparisons with the Exome methods, we used UKBB GWAS data for the GWAS and eQTL-GWAS223 methods. Across all diffusion parameters r, overall AUC values were significantly higher for GWAS224 than eQTL-GWAS in the STRING and FAVA network (P diff 0.05). A nominally significant difference in favour of GWAS compared226 to Exome was only observed in the STRING network at r values of 0.4, 0.6 and 0.8 (P diff of 0.0262,227 7.36e-3 and 0.0146, respectively). No statistical differences were observed between the eQTL-GWAS228 and Exome method except for a nominally significant difference in favour of eQTL-GWAS at r = 0.2 in229 the CoXRNAseq network (Pdiff = 0.0113).230 231 When investigating the network connectivity, we observed that drug target genes were significantly more232 likely to be hub genes (Figure 5c, Figure S8). This observation was particularly strong in the STRING233 network (mean log-degree = 13.0 vs 12.3, Pdiff = 6.6e-284 for DrugBank/DGIdb), but also present in the234 co-expression networks (∆ log-degree = 0.064, Pdiff = 0.011 for CoXRNAseq; ∆ log-degree = 0.3, Pdiff235 = 6.6e-11 for FAVA). As a consequence, the network’s node degree was found to be a good predictor236 of drug targets, and the best performance was found for the network degree in STRING (overall AUC =237 77.6%, overall OR = 8.71). Given this bias, we generated random initial disease gene scores and de-238 termined to which extent genetically-informed p0 distributions performed better compared to random p0239 distributions. Although GWAS, eQTL-GWAS and Exome methods had significantly higher AUC values240 than random score distributions for any givenr value in the STRING network (Pdiff < 1.62e-7; Table S13),241 the performance of a mildly diffused (r= 0.8) random score (which is unaware of the target disease) per-242 formed significantly better than any disease gene prioritisation method without diffusion (Pdiff of 4.18e-6,243 3.58e-10 and 2.10e-12 compared to GWAS, eQTL-GWAs and Exome, respectively). In line with this244 observation, the network degree was still significantly better than gene prioritization methods at r = 0.2245 18 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint (Pdiff of 8.98e-6, 9.87e-13 and 1.89e-11 compared to GWAS, eQTL-GWAs and Exome, respectively).246 0.5 2.0 8.0 1 0.8 0.6 0.4 0.2 0 restart parameter r OR STRING 0.5 2.0 8.0 1 0.8 0.6 0.4 0.2 0 restart parameter r OR CoXRNAseq 0.5 1.0 2.0 4.0 8.0 1 0.8 0.6 0.4 0.2 0 restart parameter r OR FAVA GWAS eQTL−GWAS Exome pQTL−GWAS Random 0 1000 2000 7.5 10.0 12.5 15.0 log−degree Gene count STRING ; ∆ = 0.75 ; p = 6.6e−284 0 500 1000 1500 2 4 6 8 log−degree Gene count CoXRNAseq ; ∆ = 0.064 ; p = 0.011 0 200 400 600 7 9 11 13 log−degree Gene count FAVA ; ∆ = 0.3 ; p = 6.6e−11 Drug target gene no yes 0.4 0.5 0.6 0.7 0.8 1 0.8 0.6 0.4 0.2 0 restart parameter r AUC STRING 0.4 0.5 0.6 0.7 0.8 1 0.8 0.6 0.4 0.2 0 restart parameter r AUC CoXRNAseq 0.4 0.5 0.6 0.7 0.8 1 0.8 0.6 0.4 0.2 0 restart parameter r AUC FAVA GWAS eQTL−GWAS Exome pQTL−GWAS Random a b No diffusion Network degree No diffusion Network degree c 19 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 5: Effect of network diffusion to prioritize drug target genes. a Boxplots showing the area under the receiver operating characteristic curve (AUC) values for each network type (STRING, CoXRNAseq and FAVA) and method at different restart parameter values r. AUC values were calculated for each of the thirty traits, and drug target genes were defined by DrugBank/DGIdb. At an r value of 1 (no network diffusion), the analysis corresponds to the results in Figure 3b, and at an r value of 0, the gene prioritization rank is simply based on the degree of the network nodes. At r < 1, the background genes are the genes reported in the respective network. The star next to the pQTL-GWAS method signals that the set of testable genes for this method is enriched for drug target genes and therefore higher AUC values were obtained when adding background genes with zero-valued initial scores. b Odds ratios (ORs) between prioritized genes (top 1%) and drug target genes for each network type and method at different r values across the thirty traits (same drug target and background genes as in a). The OR was set to 1 for traits with no identified drug target genes. c Histograms showing the degree distribution of drug target genes and non-drug target genes in each network. The difference in log-degree (∆) and the p-values from two-sided t-tests are shown in the titles. In a and b, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima (Q1 – 1.5 · IQR) to maxima (Q3 + 1.5 · IQR) with points above or below representing potential outliers. Examples of prioritized genes through network diffusion247 In the following, we describe several examples for which drug targets figured among the top 1% genes248 only after network diffusion (complete list in Table S14). Amyloid-beta precursor protein (APP) targeted249 by the monoclonal antibody aducanumab in the treatment of Alzheimer’s disease was ranked 506 (top250 2.7%) prior and 152 (top 0.8%) after diffusion on the STRING network (r = 0.6; Figure 6a) based on the251 eQTL-GWAS method. Prioritization was largely influenced by its interacting neighbour Apolipoprotein E252 (APOE) which was the top 5 ranked gene for Alzheimer’s disease. Tumor necrosis factor (TNF), a drug253 target in the treatment of inflammatory diseases such as psoriasis, was ranked 1,558 (top 8%; Exome-254 Psoriasis) prior and 182 (top 0.98%; r = 0.6) post-propagation in the STRING network (Figure 6b).255 While initially the drug target F2 (Coagulation Factor II, Thrombin) for VTE (venous thromboembolism)256 ranked only in the top 2% it moved up to the top 1% regardless of the network used for diffusion at r =257 0.6 (top 0.9%, 0.6% and 0.7% for STRONG, CoXRNAseq and FAVA, respectively). In the STRING and258 CoXRNAseq networks, this boost could largely be attributed to the interacting fibrinogen genes (FGA,259 FGB and FGG) that ranked in the top 0.06% (Figure 6c).260 20 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint APP NCSTN APH1A PSEN1 APBA2 APBB1 BACE1 APBA1 SORL1 APOE NAE1 FGB FGA AHSG UGT2B10 F2 ITIH2 APOH SLC17A2 C8A APOA2 ALB FGB FGA AHSG UGT2B10 F2 ITIH2 APOH SLC17A2 C8A APOA2 ALB C4A C4B ITIH4 ITIH2 F12 C7 F2 VTN SERPINF2 PLG KNG1 C4A C4B ITIH4 ITIH2 F12 C7 F2 VTN SERPINF2 PLG KNG1 F2 FGG FGB FGA THBD SERPINC1 SERPIND1 F2R F2RL3 CPB2 F2RL2 F2 FGG FGB FGA THBD SERPINC1 SERPIND1 F2R F2RL3 CPB2 F2RL2 a b c r = 1 r = 0.6 VTE STRING CoXRNAseq FAVA GWAS r = 0.6 r = 1 STRING eQTL-GWAS Exome Psoriasis STRING r = 1 r = 0.6 TNF TNFRSF1A RIPK1 TRADD TNFRSF1B TRAF2 F ADD IKBKB IL10 IL6 IL4 TNF TNFRSF1A RIPK1 TRADD TNFRSF1B TRAF2 F ADD IKBKB IL10 IL6 IL4 APP NCSTN APH1A PSEN1 APBA2 APBB1 BACE1 APBA1 SORL1 APOE NAE1 1.2e−05 4.5e−04 1.2e−05 2.5e−03 Alzheimer 7.5e−06 2.8e−03 21 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Figure 6: Examples illustrating network diffusion to prioritize drug target genes. a Top ten network neighbours of drug target APP (brown circle) and their prioritization values (i.e., normalized node proba- bilities) of the eQTL-GWAS method for Alzheimer’s disease are shown before (r= 1) and after diffusion (r = 0.6) on the STRING network. b Same representation as in a showing Exome prioritization values for psoriasis and tumor necrosis factor (TNF) drug target. c Top ten network neighbours of drug target F2 (Coagulation Factor II, Thrombin) in the STRING, CoXRNAseq and FAVA networks. GWAS prioriti- zation values for venous thromboembolism (VTE) are shown before (r = 1) and after diffusion (r = 0.6) on each network. In each network example (a-c), the drug target gene was among the top 1% prioritized genes only after diffusion at r = 0.6. Discussion261 We conducted a comprehensive benchmarking between different genetically informed approaches262 (GWAS, QTL-GWAS and Exome) combined with network diffusion to prioritize drug target genes.263 The strength of our analysis lies in the side-by-side comparison of gene prioritization methods that264 individually have proven to be successful in identifying drug targets. Recently, methods have emerged265 that combine multiple genetic predictors to derive an aggregate score often using machine-learning266 techniques [27, 41, 42]. These scores demonstrated high enrichment for drug targets but reveal little267 about underlying molecular mechanisms. Our aim was to disentangle the importance of the choice of268 the ground truth (i.e., drug target genes), the input data (such as molecular QTLs, WES) in combination269 with different molecular networks to highlight added benefits while also exposing weaknesses compared270 to using GWAS data alone.271 272 Adjusting for differences in background genes and data origins, GWAS yielded higher AUC than273 eQTL- and pQTL-GWAS, but no significant difference was found with Exome. Genes prioritized by274 the Exome method were different from those identified by the GWAS and QTL-GWAS methods which275 was also reflected in the identified drug targets. While this could imply that rare- and common variant276 genetic architectures are complementary, differences could also be due to power issues. Possibly,277 with increased sample size the implicated genes will converge, but the extent to which they can be278 perturbed by regulatory vs rare coding variants might remain different. Considering ORs, we lacked279 statistical power to claim significant differences between methods since the number of drug targets280 22 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint among top 1% prioritized genes can be very low. Overall enrichment ORs for drug targets were 2.17,281 2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.282 Although ORs for the pQTL-GWAS method may seem lower, it should be noted that testable proteins283 (i.e., proteins with pQTLs) accounted for ∼10% of GWAS testable genes. On the same background284 genes, ORs for the tissue-wide and blood-only eQTL-GWAS methods were 1.38 and 1.22, respectively.285 For the AUC metric, no significant difference between eQTL-GWAS and pQTL-GWAS was found. In286 the method comparisons, we considered multiple drug target gene definitions. The number of targets287 per drug drastically differed between ChEMBL and the DGIdb or STITCH databases due to differences288 in their construct. Drug target genes in the ChEMBL database are manually curated and should not289 contain false positives but it remains debatable whether to consider only primary or also secondary290 target genes. For instance, ChEMBL only lists HMGCR as a drug target for statins, whereas the DGIdb291 database also includes APOA5, APOB and APOE among others. For this reason, we considered292 different databases and present enrichment results for both broad and narrow drug target definitions,293 as well as aggregates.294 295 Network diffusion was beneficial for prioritizing drug target genes with weaker genetic support. A296 remarkable increase in drug target identification was achieved when using the STRING network.297 However, this improvement may be due to a circularity in the data generation process leading to drug298 targets being much more likely to also be hub genes. Although genetically-informed methods performed299 better than random distributions, the STRING network node degrees resulted in the highest AUC values300 overall. Thus, care has to be taken when relying on literature-derived gene-gene interactions as ag-301 gressive diffusion will point to the same drug target genes, irrespective of the disease, and the intrinsic302 bias stemming from under- and over-studied genes may hinder the discovery of new drug targets.303 The improvements made with co-expression networks, which do not suffer from publication/curation304 biases, were minor in comparison. Although significant with the AUC metric, ORs were not significantly305 increased with a diffusion of r = 0.6 as compared to no diffusion for any of the methods.306 307 23 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Among the set of measured proteins (which itself was enriched for drug target genes), protein levels of308 drug target genes exhibited lower heritabilities and higher polygenicities than non-drug target genes.309 The same trend, but to a lesser extent, was observed on the transcript level. Additionally, drug target310 genes had stronger network connections than non-drug target genes, even in unbiased co-expression311 networks. Together, these observations suggest a tendency for drug targets to be evolutionary312 constrained and as a result are more protected from genomic perturbations.313 314 Several limitations should be considered. First, we do not take into account directionality of therapeutic315 and genetic effects, i.e., whether the drug is an agonist or antagonist. Although found to be less316 performant than GWAS, QTL-GWAS methods have the advantage of specifying directionality, as317 opposed to gene scores from the GWAS approach which ignores SNP effect directions. Second, the318 used molecular QTL data sets cover only a small fraction of possible intermediate traits through which319 SNPs exert their disease-inducing effects [43]. Third, we only focus on common genetic variants when320 associating transcript and protein levels. With the advent of coupled rare variant-protein level data,321 either from populations enriched for rare variants or sequencing data [14, 44], more powerful QTL-322 GWAS methods are likely to emerge that combine mechanistic insights gained from QTL approaches323 while capturing rare variant associations previously missed. Fourth, drug target data are sparse which324 limits the statistical power in benchmarking analyses. Given the required resources to test a drug325 target in clinical settings, focusing on top ranking genes is of most interest. This scenario is best326 described with a threshold that defines highly prioritized genes for enrichment analyses. However,327 ROC curves that quantify the performance at all prioritization thresholds (i.e. use all data at hand)328 were better powered to detect subtle differences between methods. Finally, our analysis compares329

Methods

using historical drug discovery data as the ground truth. This data is highly biased with330 G-protein-coupled receptors being targets of a third of FDA-approved drugs [45]. Many other genes331 may be effective targets, but have never been tested in clinical trials. Thus, our results may not reflect332 how well the tested genetic approaches uncover true disease genes, but rather how well they identify333 targets that were historically prioritized in drug development processes. Since the emergence of robust334 24 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint GWAS, more and more clinical trials are motivated by genetically informed targets. Thus, drug tar-335 get databases will tend to overlap better with GWAS-inspired genes, leading to artificially higher overlap.336 337 To conclude, we systematically evaluated major gene prioritization approaches for their ability to identify338 approved drug target genes. Our analyses highlight the power of harnessing multiple data sources339 by capitalizing on QTLs for mechanistic insights, sequencing data for rare variant associations, GWAS340 when molecular QTL signals are missing and network propagation to leverage gene-gene interactions.341 Methods342 GWAS data343 We used the largest (to-date), publicly available GWAS summary statistics for each analyzed condi-344 tion (Table S1). GWAS data came mostly from consortia specific to the respective disease, and were345 often a meta-analysis comprising the UKBB. Twenty-four out of the 30 conditions were case/control346 studies, the remaining 6 being continuous traits: diastolic and systolic blood pressure (DBP and SBP , re-347 spectively [46]), low-density lipoprotein and total cholesterol (LDL and TC, respectively [47]), estimated348 glomerular filtration rate (eGFR [48]) and heel bone mineral density ([47]) proxying chronic kidney dis-349 ease (CKD) and osteoporosis, respectively. For four traits with low case count in the UK Biobank (<350 20,000; chronic obstructive pulmonary disease (COPD), endometriosis, pneumonia and psoriasis) and351 no large-scale GWAS meta-analysis available, we performed a meta-analysis between the UK Biobank352 [47] and FinnGen [49] using METAL [50].353 GWAS gene scores354 We used PascalX [9, 51] to compute gene scores based on GWAS summary statistics. The software355 takes as input GWAS p-values, gene annotations and LD structure. SNPs are assigned to genes and356 their squared z-scores are summed. This sum, under the null, was shown to follow a weighted chi-357 square distribution with weights being defined by the local LD structure from which gene p-values can be358 derived [9]. We applied PascalX with default parameters (gene ± 50 kB) on protein-coding genes using359 25 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint the Ensembl identifiers and annotations (Ensembl GRCh37.p13 version) and the UK10K reference panel360 [52]. Across traits, ∼19,150 protein-coding genes could be tested which were ranked by their PascalX361 p-value.362 Molecular QTL-GWAS gene scores363 We integrated molecular quantitative trait loci (QTL) and GWAS summary statistics using Mendelian364 randomization (MR) implemented in the smr-ivw software [53, 22]. The exposure (transcript or protein365 levels) and outcome disease were instrumented with independent genetic variants, also called instru-366 mental variables (IVs; r2 < 0.01) and used to calculate putative causal effect estimates of the exposure367 on the outcome (β MR). IVs were required to be strongly associated to the exposure (P QTL < 1e-6) and368 had to pass the Steiger filter ensuring no significantly stronger effect on the outcome than on the ex-369 posure [54]. We used expression QTLs (eQTLs) from the eQTLGen consortium [13] (whole blood; n =370 31,684) and tissue-specific QTLs from the GTEx v8 release [55] (European ancestry; n = 65-573 for 48371 tissue types; Table S4) to estimate causal transcript-trait effects. In the eQTLGen dataset there were372 ∼12,550 protein-coding genes with at least 1 IV which increased to ∼16,250 when integrating the GTEx373 dataset. MR results from both datasets (whole blood from eQTLGen and 49 tissues from GTEx) were374 aggregated by considering the MR causal effect with the lowest p-value across tissues (Table S4-5).375 Protein QTLs (pQTLs) from the deCODE study [14] (whole blood; n = 35,559) were used to estimate376 protein-trait causal effects with ∼1,870 proteins having at least 1 IV. Prior to the analysis, e/pQTL and377 GWAS data were harmonized, palindromic SNPs were removed as well as SNPs with an allele frequency378 difference > 0.05 between datasets. All transcripts and proteins were mapped to Ensembl identifiers as379 provided by eQTLGen, GTEx and deCODE.380 Exome gene scores381 We used gene burden test results computed on WES data from the UK Biobank [25]. We extracted382 gene-trait associations based on putative loss of function (pLOF) and deleterious missense variants383 with MAF <1% (M3.1 nomenclature in original publication) with phenotypes matching the investigated384 conditions as indicated in Table S2. Associations were provided for ∼18,800 genes which were ranked385 26 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint by the association p-value and retrieved by the provided Ensembl identifier.386 Concordance of gene scoring methods387 We tested whether prioritized genes were similar or dissimilar between pairs of methods. First, only388 genes (based on Ensembl identifiers) that were common between the two tested methods were selected389 into the gene background. Then, prioritized genes were defined at different top percentile cut-offs (0.1%,390 0.2%, 0.5%, 1%, 2%, 3%, 5%, 7.5%, 10%). The enrichment of prioritized genes between methods was391 quantified by a Fisher’s exact test using common genes as background genes. When calculating median392 ORs, ORs of traits for which no prioritized genes overlapped at a given percentile were set to 1.393 Drug target genes394 We extracted drug target genes from public resources by combining drug-indication and drug-target links395 from various databases. A given disease/indication was linked to a drug if the drug was indicated to be396 prescribed for the selected indication and subsequently, the target genes of these drugs were extracted.397 For drug-indication pairs we consulted DrugBank, Ruiz et al. and ChEMBL:398 • DrugBank 5.0 [35] (download: May 2022): DrugBank indications are manually curated from drug399 labels and underwent an expert review process. Drug indications have their own DrugBank condi-400 tion numbers and drugs their DrugBank identifiers.401 • Ruiz et al. [36]: A drug-disease dataset was created by querying multiple sources such as the402 Drug Repurposing Database, the Drug Repurposing Hub, and the Drug Indication Database and403 extracting information from drug labels, DrugBank and the American Association of Clinical Tri-404 als Database. Drug–disease pairs were filtered for FDA-approved treatment relationships. This405 dataset uses NLM UMLS CUIDS identifiers (National Library of Medicine -Unified Medical Lan-406 guage System Controlled Unique Identifier) for diseases and DrugBank identifiers for drugs.407 • ChEMBL [37] (download: May 2022): ChEMBL drug indications are extracted from multiple408 sources including DailyMed package inserts, Anatomical Therapeutic Chemical (ATC) classifica-409 tion and ClinicalTrials.gov. Mapping of disease terms to Medical Subject Headings (MeSH) vocab-410 27 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint ulary and the Experimental Factor Ontology (EFO) is done through a combination of text-mining,411 automated mapping and manual curation/validation. Drugs are reported with ChEMBL identifiers.412 The mapping of GWAS traits to the drug indication identifiers of the respective database is shown in413 Table S6.414 415 Drug target genes were extracted from the DGIdb, STITCH and ChEMBL databases:416 • Drug Gene Interaction database (DGIdb) 4.0 [38] (release: January 2021): Aggregated drug-gene417 interactions from multiple sources including DrugBank, Drug Target Commons, the Therapeutic418 Target Database and Guide to Pharmacology. Genes were matched to Ensembl identifiers using419 the provided gene vocabulary file. Drugs were reported through DrugBank or ChEMBL identifiers,420 and mapping from ChEMBL to DrugBank identifiers was done with UniChem [56], using PubChem421 IDs as intermediates.422 • Search Tool for Interacting CHemicals (STITCH) 5.0 [39]: Aggregated drug-protein interaction423 data from high-throughput experiments data, manually curated datasets and prediction methods.424 Only high confidence drug-protein relationships (confidence score ≥ 700) of the type “inhibition”425 and “activation” were considered. STITCH uses PubChem Chemical Identifiers (CID) for drugs426 and mapping to DrugBank IDs was done through the chemical sources file provided by STITCH.427 Protein Ensembl identifiers were mapped to gene Ensembl identifiers using biomaRt (GRCh37,428 v2.50.3)[57].429 • ChEMBL [37] (download: May 2022): ChEMBL provides drug targets which have been manually430 curated from literature. Drug targets are identified by ChEMBL IDs with mapping to UniProt Ac-431 cessions provided by ChEMBL. UniProt identifiers were then mapped to gene Ensembl identifiers432 through the UniProt REST API [58].433 In this analysis we considered drug target genes resulting from the following combinations: Drug-434 Bank/DGIdb, DrugBank/STITCH, Ruiz/DGIdb, Ruiz/STITCH, and ChEMBL/ChEMBL. The number of435 drugs and drug target genes per indication is shown in Table S7.436 28 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Drug target enrichment and AUC calculations437 Enrichment for drug target genes was calculated through two-sided Fisher’s exact tests. A contingency438 table was constructed based on testable genes (i.e., background genes), with genes categorized439 into prioritized (top 1% or 5% for the pQTL-GWAS) and drug target genes. In rare instances (i.e.,440 pQTL-GWAS background genes and ChEMBL/ChEMBL drug targets) where diagonal values were 0,441 these were changed to 1. If no prioritized gene coincided with a drug target gene, the resulting OR442 was set to 1 (for visualization purposes this was not done in barplots where each trait was shown443 individually). AUC values and standard errors were calculated using the R package pROC v1.15.3 [59].444 445 Log-OR and AUC values (both are denotedbi herein) were aggregated across traits and drug databases446 (m = 30 · 5 = 150 observations per method) as follows:447 ¯b = 1 m mX i bi (1) with corresponding variance:448 var(¯b) = 1′ · S · R · S · 1/m2 (2) where S is a diagonal matrix of size mxm containing standard errors of bi and R is the correlation449 matrix between drug databases and traits. This matrix was derived from the Kronecker product of the450 drug database correlation matrix and phenotypic trait correlation matrix (Table S8). The drug database451 correlation matrix was derived on the gene level (i.e., 1 if the gene was a drug target for any of the 30452 traits, 0 if not) and the phenotypic trait correlation on individual-level data from the UKBB (codes in Table453 S2). ¯b was referred to as the overall AUC/ log-OR (overall OR after an exponential transformation).454 455 To calculate the statistical difference of ¯b1 and ¯b2 for method 1 and 2, respectively, we derived the456 variance of the difference as follows:457 29 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint var(¯b1 − ¯b2) = var(¯b1) + var(¯b2) − 2 · cov(¯b1,¯b2) (3) with cov(¯b1,¯b2) ≈ r × 1′ · S1 · R · S2 · 1/m2 , where r is the empirical correlation between b1 and b2.458 From the resulting z-score, a two-sided p-value was calculated.459 Transcript and protein level heritabilities and polygenicity460 Transcript and protein level heritabilities were estimated from QTL effects. Standardized QTL effects461 ( ˆβG) were approximated by dividing SNP z-scores by the square root of the sample size. The corre-462 sponding variance (var( ˆβG)) equals the inverse of the sample size. The cis heritability (ˆh2 cis) could then463 be estimated by summing up effects of independent (r 2 < 0.01) and significant (p-value < 1e-6) QTLs464 in proximity of the transcript/protein (± 500 kB) while taking into account their variance:465 ˆh2 cis = X i  ˆβ2 Gi − var(ˆβGi)  (4) Protein heritabilities were based on the deCODE plasma protein dataset [14] and transcript heritabilities466 for whole blood on the eQTLGen dataset [13]. Tissue-wide transcript heritabilities were based on eQTL467 effects from the tissue in which the MR effect was the most significant [55].468 469 To calculate the difference in heritabilities and polygenicities between drug target and non-drug target470 genes, we considered all transcripts and proteins measured in the respective study which were classified471 accordingly. Per trait, the difference in heritability was then calculated through a two-sided t-test. For472 the polygenicity analysis, we considered the number of independent (r2 < 0.01) and significant (p-value473 < 1e-6) QTLs associated to a transcript/protein. Note that this proxy for polygenicity is biased, as474 for less heritable omics entities we have less power to detect the independent signals, and may look475 less polygenic. We then conducted two-sided Wilcoxon tests to determine the difference in number of476 instrumental variables (IVs). Heritability and polygenicity tests were only performed for traits with at477 least three drug targets within the respective set of measured transcripts/proteins. Note that in case a478 30 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint transcript or protein was reported as measured in the study, but had no associated QTL, its heritability479 and number of IVs were set to zero.480 Networks481 To calculate network diffusion scores, we used the following three networks:482 • Search Tool for Retrieval of Interacting Genes/Proteins (STRING) v11 [32]: The protein-protein483 (PPI) interaction network results from predictions based on genomic context information, co-484 expression, text-mining, experimental biochemical/genetic data and curated databases (curated485 pathways and protein-complex knowledge). Protein Ensembl identifiers were mapped to gene En-486 sembl identifiers using biomaRt (GRCh37, v2.50.3)[57]. We use interaction confidence scores as487 edge weights.488 • CoXRNAseq [33]: This network was constructed by first performing a principal component analy-489 sis on the gene co-expression correlation matrix of 31,499 RNA-seq samples. Reliable principal490 components were retained from which the final network was constructed via Pearson correlations.491 We filtered pairwise interactions to only retain those with z-scores above 4. Genes were reported492 with Ensembl identifiers and z-scores were used as edge weights.493 • Functional Associations using Variational Autoencoders (FAVA) [34]: This network is based on494 single cell RNA-seq read-count data from the Human Protein Atlas and proteomics data from the495 PRoteomics IDEntifications (PRIDE) database. First, the high-dimensional expression data was496 reduced into a latent space using variational autoencoders. From this latent space, the network497 was derived via pairwise Pearson correlations. Each reported interaction has a score which we498 use as edge weight (final network reports interactions with scores above 0.15). Protein Ensembl499 identifiers were mapped to gene Ensembl identifiers using biomaRt.500 A summary of network properties is given in Table S11. In all analyses, we use weighted networks, and501 we refer to weighted node degrees (i.e., sum of edge weights linking the node of interest to adjacent502 nodes) as node degrees.503 31 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Network diffusion504 We calculated network diffusion scores based on Markov random walks. Starting from an initial node505 distribution p0, a stationary distribution is calculated based on network connectivity. This diffusion pro-506 cess depends on a restart parameter r which determines how often the random walker returns to the507 initial values. Analytically, the stationary distribution (p∞) is given by:508 p∞ = (I − (1 − r) · W )−1 · p0 (5) where W is the column-normalized weighted adjacency matrix and I the identity matrix of the same509 dimension as W [60]. The initial node distribution p0 was determined by the squared z-scores derived510 from the gene p-values (normalized to sum up to 1). Genes that could not be tested by a given method511 had their initial value set to 0. Additionally, we tested the performance of network diffusion on random512 initial distributions p0. For each trait, a random distribution was generated which all were different, but513 consistent across analyses. Resulting network diffusion scores p∞ were ranked for AUC calculations,514 and the top 1% scored genes were used in the enrichment analyses.515 516 Network manipulations, visualization and degree calculations were performed with the R igraph package517 v1.3.5 [61].518 Enrichment of available proteins for drug targets519 We conducted binomial tests to verify whether the set of testable (i.e., at least 1 pQTL) and measured520 proteins ( ∼1,870 and ∼4,450, respectively) were enriched for drug target genes. We performed the521 analysis on each of the five drug target definitions and proceeded as follows: 1) we extracted the number522 of testable/measured proteins that are drug targets (“number of successes”), 2) considering all protein-523 coding autosomal genes (19,430), we extracted those that are drug targets (“number of trials”), 3) we524 determined the proportion of testable/measured proteins among all protein-coding genes (“expected525 probability of success”). From these numbers, we conducted two-sided exact binomial tests (Table526 32 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint S15).527 Data availability Whole blood expression QTLs are from the eQTLGen eQTL meta-analysis and are available at https: //www.eqtlgen.org/cis-eqtls.html. Tissue-wide expression QTLs are from the GTEx project and are available at https://gtexportal.org/home/datasets. Plasma protein QTLs are from the de- CODE study and are available at https://www.decode.com/summarydata/. Summary statistics from whole exome gene burden tests are available in the GWAS Catalog (accession IDs are in Table S2). Genetic and phenotypic data from the UK Biobank Resource are available to approved researchers. GWAS summary statistics from the UK Biobank are available athttp://www.nealelab.is/uk-biobank and https://pan.ukbb.broadinstitute.org. GWAS summary statistics from FinnGen are available at https://www.finngen.fi/en/access_results. GWAS summary statistics for multiple sclerosis (MS) are available by application from https://imsgc.net/?page_id=31. Full list of GWAS summary statis- tics used in this study is in Table S1-3, all of which are publicly available. UK10K individual-level data are available upon request (https://www.uk10k.org/data_access.html). Code availability GWAS calculations were performed with REGENIE which is available athttps://github.com/rgcgithub/ regenie. GWAS meta-analyses were performed with METAL which is available at https://github. com/statgen/METAL. Gene scoring was performed with the PascalX software which is available at https://github.com/BergmannLab/PascalX. QTL Mendelian randomization analyses were performed with the SMR-IVW software which is available at https://github.com/masadler/smrivw. Competing interests The authors declare that they have no competing interests. 33 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Authors’ contributions MCS and ZK conceived and designed the study. MCS performed statistical analyses. PD provided guidance on statistical analyses. ZK supervised all statistical analyses. CA contributed to the collection and interpretation of pharmacological and biological data. All the authors contributed by providing advice on interpretation of results. MCS and ZK drafted the manuscript. All authors read, approved, and provided feedback on the final manuscript.

Acknowledgements

This work was supported by the Swiss National Science Foundation (310030 189147) to Z.K. This re- search has been conducted using the UK Biobank Resource under Application Number 16389. LD was calculated based on the UK10K data resource (EGAD00001000740, EGAD00001000741). Com- putations we performed on the JURA cluster of the University of Lausanne. We also would like to acknowledge the participants and investigators of the UK Biobank and FinnGen study. We thank Daniel Krefl for his help and support in implementing the PascalX software and Liza Darrous for critical reading of the draft.

References

[1] Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen, Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, et al. The support of human genetic evidence for approved drug indications. Nature genetics, 47(8):856–860, 2015. [2] Emily A King, J Wade Davis, and Jacob F Degner. Are drug targets with genetic support twice as likely to be approved? revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS genetics, 15(12):e1008489, 2019. [3] Stacey L Edwards, Jonathan Beesley, Juliet D French, and Alison M Dunning. Beyond gwass: illuminating the dark road from association to function. The American Journal of Human Genetics, 93(5):779–797, 2013. 34 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [4] Chen Cao and John Moult. Gwas and drug targets. BMC genomics, 15(4):1–14, 2014. [5] Vivian Tam, Nikunj Patel, Michelle Turcotte, Y ohan Boss´e, Guillaume Par´e, and David Meyre. Bene- fits and limitations of genome-wide association studies. Nature Reviews Genetics, 20(8):467–484, 2019. [6] Steven Gazal, Omer Weissbrod, Farhad Hormozdiari, Kushal K Dey, Joseph Nasser, Karthik A Jagadeesh, Daniel J Weiner, Huwenbo Shi, Charles P Fulco, Luke J O’Connor, et al. Combining snp-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nature Genetics, pages 1–10, 2022. [7] Jimmy Z Liu, Allan F Mcrae, Dale R Nyholt, Sarah E Medland, Naomi R Wray, Kevin M Brown, Nicholas K Hayward, Grant W Montgomery, Peter M Visscher, Nicholas G Martin, et al. A versatile gene-based test for genome-wide association studies. The American Journal of Human Genetics, 87(1):139–145, 2010. [8] Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, and Danielle Posthuma. Magma: generalized gene-set analysis of gwas data. PLoS computational biology, 11(4):e1004219, 2015. [9] David Lamparter, Daniel Marbach, Rico Rueedi, Zolt ´an Kutalik, and Sven Bergmann. Fast and rigorous computation of gene and pathway scores from snp-based summary statistics. PLoS com- putational biology, 12(1):e1004714, 2016. [10] John Lonsdale, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor Shad, Richard Hasz, Gary Walters, Fernando Garcia, Nancy Y oung, et al. The genotype-tissue expres- sion (gtex) project. Nature genetics, 45(6):580–585, 2013. [11] Benjamin B Sun, Joseph C Maranville, James E Peters, David Stacey, James R Staley, James Blackshaw, Stephen Burgess, Tao Jiang, Ellie Paige, Praveen Surendran, et al. Genomic atlas of the human plasma proteome. Nature, 558(7708):73–79, 2018. [12] Lasse Folkersen, Stefan Gustafsson, Qin Wang, Daniel Hvidberg Hansen, ˚Asa K Hedman, Andrew Schork, Karen Page, Daria V Zhernakova, Y ang Wu, James Peters, et al. Genomic and drug target 35 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature metabolism, 2(10):1135– 1148, 2020. [13] Urmo V ˜osa, Annique Claringbould, Harm-Jan Westra, Marc Jan Bonder, Patrick Deelen, Biao Zeng, Holger Kirsten, Ashis Saha, Roman Kreuzhuber, Harm Brugge, et al. Large-scale cis-and trans- eqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nature genetics, pages 1–11, 2021. [14] Egil Ferkingstad, Patrick Sulem, Bjarni A Atlason, Gardar Sveinbjornsson, Magnus I Magnusson, Edda L Styrmisdottir, Kristbjorg Gunnarsdottir, Agnar Helgason, Asmundur Oddsson, Bjarni V Hall- dorsson, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics, 53(12):1712–1721, 2021. [15] Benjamin B Sun, Joshua Chiou, Matthew Traylor, Christian Benner, Yi-Hsiang Hsu, Tom G Richard- son, Praveen Surendran, Anubha Mahajan, Chloe Robins, Steven G Vasquez-Grinnell, et al. Ge- netic regulation of the human plasma proteome in 54,306 uk biobank participants. BioRxiv, 2022. [16] Claudia Giambartolomei, Damjan Vukcevic, Eric E Schadt, Lude Franke, Aroon D Hingorani, Chris Wallace, and Vincent Plagnol. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet, 10(5):e1004383, 2014. [17] Farhad Hormozdiari, Martijn Van De Bunt, Ayellet V Segre, Xiao Li, Jong Wha J Joo, Michael Bilow, Jae Hoon Sul, Sriram Sankararaman, Bogdan Pasaniuc, and Eleazar Eskin. Colocalization of gwas and eqtl signals detects target genes.The American Journal of Human Genetics, 99(6):1245–1260, 2016. [18] Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx, Rick Jansen, Eco JC De Geus, Dorret I Boomsma, Fred A Wright, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nature genetics, 48(3):245–252, 2016. [19] Alvaro N Barbeira, Scott P Dickinson, Rodrigo Bonazzola, Jiamao Zheng, Heather E Wheeler, Jason M Torres, Eric S Torstenson, Kaanan P Shah, Tzintzuni Garcia, Todd L Edwards, et al. 36 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint Exploring the phenotypic consequences of tissue specific gene expression variation inferred from gwas summary statistics. Nature communications, 9(1):1–20, 2018. [20] Y ang Wu, Jian Zeng, Futao Zhang, Zhihong Zhu, Ting Qi, Zhili Zheng, Luke R Lloyd-Jones, Ric- cardo E Marioni, Nicholas G Martin, Grant W Montgomery, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nature communications, 9(1):1–14, 2018. [21] Eleonora Porcu, Sina R ¨ueger, Kaido Lepik, Federico A Santoni, Alexandre Reymond, and Zolt ´an Kutalik. Mendelian randomization integrating gwas and eqtl data reveals genetic determinants of complex and clinical traits. Nature communications, 10(1):1–12, 2019. [22] Marie C Sadler, Chiara Auwerx, Kaido Lepik, Eleonora Porcu, and Zolt ´an Kutalik. Quantifying the role of transcript levels in mediating dna methylation effects on complex traits and diseases.Nature Communications, 13(1):1–14, 2022. [23] Elizabeth T Cirulli, Simon White, Robert W Read, Gai Elhanan, William J Metcalf, Francisco Tanud- jaja, Donna M Fath, Efren Sandoval, Magnus Isaksson, Karen A Schlauch, et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nature communications, 11(1):1–10, 2020. [24] Jack A Kosmicki, Julie E Horowitz, Nilanjana Banerjee, Rouel Lanche, Anthony Marcketta, Evan Maxwell, Xiaodong Bai, Dylan Sun, Joshua D Backman, Deepika Sharma, et al. Pan-ancestry exome-wide association analyses of covid-19 outcomes in 586,157 individuals. The American Journal of Human Genetics, 108(7):1350–1355, 2021. [25] Joshua D Backman, Alexander H Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou, Michael D Kessler, Christian Benner, Daren Liu, Adam E Locke, Suganthi Balasubramanian, et al. Exome sequencing and analysis of 454,787 uk biobank participants. Nature, 599(7886):628–634, 2021. [26] Emre Guney, J ¨org Menche, Marc Vidal, and Albert-L ´aszl´o Bar´abasi. Network-based in silico drug efficacy screening. Nature communications, 7(1):1–13, 2016. 37 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [27] Hai Fang, Hans De Wolf, Bogdan Knezevic, Katie L Burnham, Julie Osgood, Anna Sanniti, Alicia Lled´o Lara, Silva Kasela, Stephane De Cesco, J ¨org K Wegner, et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nature genetics, 51(7):1082–1091, 2019. [28] Aidan MacNamara, Nikolina Nakic, Ali Amin Al Olama, Cong Guo, Karsten B Sieber, Mark R Hurle, and Alex Gutteridge. Network and pathway expansion of genetic disease associations identifies successful drug targets. Scientific reports, 10(1):1–11, 2020. [29] Yingnan Han, Clarence Wang, Katherine Klinger, Deepak K Rajpal, and Cheng Zhu. An integrative network-based approach for drug target indication expansion. PloS one, 16(7):e0253614, 2021. [30] Inigo Barrio-Hernandez, Jeremy Schwartzentruber, Anjali Shrivastava, Noemi del Toro, Qian Zhang, Glyn Bradley, Henning Hermjakob, Sandra Orchard, Ian Dunham, Carl A Anderson, et al. Network expansion of genetic associations defines a pleiotropy map of human cell biology.BioRxiv, 2021. [31] Katja Luck, Dae-Kyum Kim, Luke Lambourne, Kerstin Spirohn, Bridget E Begg, Wenting Bian, Ruth Brignall, Tiziana Cafarelli, Francisco J Campos-Laborie, Benoit Charloteaux, et al. A reference map of the human binary protein interactome. Nature, 580(7803):402–408, 2020. [32] Damian Szklarczyk, Annika L Gable, David Lyon, Alexander Junge, Stefan Wyder, Jaime Huerta- Cepas, Milan Simonovic, Nadezhda T Doncheva, John H Morris, Peer Bork, et al. String v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research, 47(D1):D607–D613, 2019. [33] Patrick Deelen, Sipko van Dam, Johanna C Herkert, Juha M Karjalainen, Harm Brugge, Kristin M Abbott, Cleo C van Diemen, Paul A van der Zwaag, Erica H Gerkes, Evelien Zonneveld-Huijssoon, et al. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associa- tions using large-scale gene expression analysis. Nature communications, 10(1):1–13, 2019. 38 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [34] Mikaela Koutrouli, Pau Piera L ´ındez, Robbin Bouwmeester, Lennart Martens, and Lars Juhl Jensen. Fava: High-quality functional association networks inferred from scrna-seq and proteomics data. bioRxiv, 2022. [35] David S Wishart, Y annick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. Drugbank 5.0: a major update to the drugbank database for 2018. Nucleic acids research, 46(D1):D1074–D1082, 2018. [36] Camilo Ruiz, Marinka Zitnik, and Jure Leskovec. Identification of disease treatment mechanisms through the multiscale interactome. Nature communications, 12(1):1–15, 2021. [37] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez, Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibri ´an-Uhalte, et al. The chembl database in 2017. Nucleic acids research, 45(D1):D945–D954, 2017. [38] Sharon L Freshour, Susanna Kiwala, Kelsy C Cotto, Adam C Coffman, Joshua F McMichael, Jonathan J Song, Malachi Griffith, Obi L Griffith, and Alex H Wagner. Integration of the drug– gene interaction database (dgidb 4.0) with open crowdsource efforts. Nucleic acids research, 49(D1):D1144–D1151, 2021. [39] Damian Szklarczyk, Alberto Santos, Christian Von Mering, Lars Juhl Jensen, Peer Bork, and Michael Kuhn. Stitch 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic acids research, 44(D1):D380–D384, 2016. [40] Luke J O’Connor, Armin P Schoech, Farhad Hormozdiari, Steven Gazal, Nick Patterson, and Alkes L Price. Extreme polygenicity of complex traits is explained by negative selection. The American Journal of Human Genetics, 105(3):456–476, 2019. [41] Edward Mountjoy, Ellen M Schmidt, Miguel Carmona, Jeremy Schwartzentruber, Gareth Peat, Al- fredo Miranda, Luca Fumis, James Hayhurst, Annalisa Buniello, Mohd Anisul Karim, et al. An open approach to systematically prioritize causal variants and genes at all published human gwas trait-associated loci. Nature Genetics, 53(11):1527–1533, 2021. 39 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [42] Vincenzo Forgetta, Lai Jiang, Nicholas A Vulpescu, Megan S Hogan, Siyuan Chen, John A Morris, Stepan Grinek, Christian Benner, Dong-Keun Jang, Quy Hoang, et al. An effector index to predict target genes at gwas loci. Human Genetics, pages 1–17, 2022. [43] Douglas W Y ao, Luke J O’Connor, Alkes L Price, and Alexander Gusev. Quantifying genetic effects on disease mediated by assayed gene expression levels. Nature Genetics, 52(6):626–633, 2020. [44] Ryan S Dhindsa, Oliver S Burren, Benjamin B Sun, Bram P Prins, Dorota Matelska, Eleanor Wheeler, Jonathan Mitchell, Erin Oerton, Ventzislava A Hristova, Katherine R Smith, et al. Influ- ences of rare protein-coding genetic variants on the human plasma proteome in 50,829 uk biobank participants. bioRxiv, 2022. [45] Alexander S Hauser, Sreenivas Chavali, Ikuo Masuho, Leonie J Jahn, Kirill A Martemyanov, David E Gloriam, and M Madan Babu. Pharmacogenomics of gpcr drug targets.Cell, 172(1-2):41–54, 2018. [46] Evangelos Evangelou, Helen R Warren, David Mosen-Ansorena, Borbala Mifsud, Raha Pazoki, He Gao, Georgios Ntritsos, Niki Dimou, Claudia P Cabrera, Ibrahim Karaman, et al. Genetic anal- ysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature genetics, 50(10):1412–1425, 2018. [47] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O’Connell, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature, 562(7726):203–209, 2018. [48] Matthias Wuttke, Y ong Li, Man Li, Karsten B Sieber, Mary F Feitosa, Mathias Gorski, Adrienne Tin, Lihua Wang, Audrey Y Chu, Anselm Hoppmann, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nature genetics, 51(6):957–972, 2019. [49] Mitja I Kurki, Juha Karjalainen, Priit Palta, Timo P Sipil ¨a, Kati Kristiansson, Kati Donner, Mary P Reeve, Hannele Laivuori, Mervi Aavikko, Mari A Kaunisto, et al. Finngen: Unique genetic insights from combining isolated population and national health register data. medRxiv, 2022. 40 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [50] Cristen J Willer, Yun Li, and Gonc ¸alo R Abecasis. Metal: fast and efficient meta-analysis of genomewide association scans. Bioinformatics, 26(17):2190–2191, 2010. [51] Daniel Krefl and Sven Bergmann. Bergmannlab/pascalx: Pascalx v0.0.1 (v0.0.1), 2021. https: //doi.org/10.5281/zenodo.4429922. [52] UK10K et al. The UK10K project identifies rare variants in health and disease. Nature, 526(7571):82, 2015. [53] Zhihong Zhu, Futao Zhang, Han Hu, Andrew Bakshi, Matthew R Robinson, Joseph E Powell, Grant W Montgomery, Michael E Goddard, Naomi R Wray, Peter M Visscher, et al. Integration of summary data from gwas and eqtl studies predicts complex trait gene targets. Nature genetics, 48(5):481–487, 2016. [54] Gibran Hemani, Kate Tilling, and George Davey Smith. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS genetics, 13(11):e1007081, 2017. [55] THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across hu- man tissues. Science, 369(6509):1318–1330, 2020. [56] Jon Chambers, Mark Davies, Anna Gaulton, Anne Hersey, Sameer Velankar, Robert Petryszak, Janna Hastings, Louisa Bellis, Shaun McGlinchey, and John P Overington. Unichem: a unified chemical structure cross-referencing and identifier tracking system. Journal of cheminformatics, 5(1):1–9, 2013. [57] Steffen Durinck, Paul T. Spellman, Ewan Birney, and Wolfgang Huber. Mapping identifiers for the integration of genomic datasets with the r/bioconductor package biomart. Nature Protocols, 4:1184–1191, 2009. [58] Andrew Nightingale, Ricardo Antunes, Emanuele Alpi, Borisas Bursteinas, Leonardo Gonzales, Wudong Liu, Jie Luo, Guoying Qi, Edd Turner, and Maria Martin. The proteins api: accessing key integrated protein and genome information. Nucleic acids research, 45(W1):W539–W544, 2017. 41 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint [59] Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Fr´ed´erique Lisacek, Jean-Charles Sanchez, and Markus M ¨uller. proc: an open-source package for r and s+ to analyze and compare roc curves. BMC bioinformatics, 12(1):1–8, 2011. [60] Hanghang Tong, Christos Faloutsos, and Jia-Yu Pan. Fast random walk with restart and its appli- cations. In Sixth international conference on data mining (ICDM’06), pages 613–622. IEEE, 2006. [61] Gabor Csardi, Tamas Nepusz, et al. The igraph software package for complex network research. InterJournal, complex systems, 1695(5):1–9, 2006. 42 . CC-BY 4.0 International licenseIt is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 24, 2023. ; https://doi.org/10.1101/2023.03.21.23285637doi: medRxiv preprint

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-19T08:37:55.746041+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC